Arizona Diamondbacks Pitching Prospect Joel Matos Busted For Steroids; Suspended 50 Games
A pitching prospect for the Arizona Diamondbacks has been busted for using performance-enhancing drugs.
Joel Matos, a right-handed pitcher in the Dominican Summer League, tested positive for metabolites of the drug Stanozolol, which is also known as Winstrol.
In other words, dude was juicin'.
Because of his stupidity, Matos has been suspended for 50 games, effective immediately.
Arizona Coyotes vs. San Jose Sharks
TicketsTue., Nov. 1, 7:00pm
Phoenix Suns vs. Portland Trail Blazers
TicketsWed., Nov. 2, 7:00pm
Arizona Coyotes vs. Nashville Predators
TicketsThu., Nov. 3, 7:00pm
Arizona State University Sun Devils Hockey vs. University of Michigan
TicketsFri., Nov. 4, 7:05pm
Four other players were suspended for testing positive for violating the league's drug policy. Three of them pitchers including two from the Yankees (Daury Aquino and Alexander de los Santos) and one from the Royals (Freddy Rodriguez).
All of the pitchers were caught using Stanozolol.
Jhancarlos Infante, a catching prospect with Tampa Bay, was suspended for testing positive for metabolites of the drug Boldenone.
Repeated requests for a comment from the D-Backs were unreturned.
Matos, who is only 17 years old, is a pretty big kid at six-foot-five and 200 pounds.
He appeared in four games (starting two) during the summer league thus far, and had somewhat unspectacular numbers.
Matos was 0-3 with a 4.26 ERA in 6.1 innings pitched while striking out only two.
Another downside is that Matos walked nine batters in his appearances.
With those numbers, he would fit right in with the D-Backs bullpen.
But the chances of that happening are now slim to none. Matos, who is from the Dominican Republic, probably won't be playing on a major league field anytime soon.
Get the This Week's Top Stories Newsletter
Every week we collect the latest news, music and arts stories — along with film and food reviews and the best things to do this week — so that you'll never miss Phoenix New Times' biggest stories.